Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kalvista Pharmaceuticals Inc (KALV)

Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,049,027
  • Shares Outstanding, K 51,222
  • Annual Sales, $ 49,080 K
  • Annual Income, $ -109,520 K
  • EBIT $ -191 M
  • EBITDA $ -190 M
  • 60-Month Beta -0.40
  • Price/Sales 20.41
  • Price/Cash Flow N/A
  • Price/Book 58.13

Options Overview Details

View History
  • Implied Volatility 83.95% (+1.02%)
  • Historical Volatility 68.24%
  • IV Percentile 17%
  • IV Rank 9.90%
  • IV High 296.34% on 10/23/25
  • IV Low 60.62% on 07/21/25
  • Expected Move (DTE 25) 2.93 (14.06%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 141
  • Volume Avg (30-Day) 1,264
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 20,251
  • Open Int (30-Day) 27,312
  • Expected Range 17.92 to 23.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.37
  • Number of Estimates 5
  • High Estimate $-0.06
  • Low Estimate $-0.59
  • Prior Year $-0.99
  • Growth Rate Est. (year over year) +62.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.94 +30.89%
on 03/24/26
21.31 -2.04%
on 04/01/26
+3.87 (+22.76%)
since 03/20/26
3-Month
14.23 +46.71%
on 02/17/26
21.31 -2.04%
on 04/01/26
+5.56 (+36.32%)
since 01/20/26
52-Week
9.83 +112.31%
on 06/24/25
21.31 -2.04%
on 04/01/26
+8.87 (+73.92%)
since 04/17/25

Most Recent Stories

More News
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference, April 15, 2026, at 10:15 a.m....

KALV : 20.94 (+2.25%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted five newly-hired employees inducement options to purchase an aggregate...

KALV : 20.94 (+2.25%)
KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference

Interim data show sebetralstat enables early, effective treatment of hereditary angioedema (HAE) attacks in children with favorable safety and tolerability

KALV : 20.94 (+2.25%)
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

$49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms...

KALV : 20.94 (+2.25%)
KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update

$49.1 million global net product revenue of EKTERLY ® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms...

KALV : 20.94 (+2.25%)
KalVista Faces Critical Test as Losses Expected to Narrow Sharply

KALV : 20.94 (+2.25%)
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference

New interim data from the KONFIDENT-KID trial evaluating sebetralstat in children aged 2-11 accepted for late-breaking oral presentation

KALV : 20.94 (+2.25%)
KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Wednesday, March 25, 2026, at 8:30 a.m. ET to review the Company’s eight months fiscal year 2025 financial results...

KALV : 20.94 (+2.25%)
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Compensation Committee of KalVista’s Board of Directors granted one newly-hired employee inducement options to purchase an aggregate...

KALV : 20.94 (+2.25%)
KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)

Presentations highlight patient preference for sebetralstat, early treatment as the strongest driver of response, and sustained effectiveness with use in clinical trials

KALV : 20.94 (+2.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

3rd Resistance Point 22.00
2nd Resistance Point 21.40
1st Resistance Point 20.94
Last Price 20.94
1st Support Level 19.88
2nd Support Level 19.28
3rd Support Level 18.82

See More

52-Week High 21.31
Last Price 20.94
Fibonacci 61.8% 16.92
Fibonacci 50% 15.57
Fibonacci 38.2% 14.21
52-Week Low 9.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.